Opinion
Video
Seladelpar for Treatment of PBC
Key Takeaways
- Seladelpar demonstrates sustained efficacy in improving liver biochemistry and symptom relief in primary biliary cholangitis (PBC) over long-term use.
- The drug modulates lipid metabolism and inflammation, crucial mechanisms in managing PBC, enhancing its therapeutic potential.
The panel of experts review the long-term data on the recently FDA-approved PPAR-δ agonist seladelpar for primary biliary cholangitis (PBC), focusing on its efficacy, safety, and impact on liver biochemistry markers over time.
Video content above is prompted by the following:
- Could you discuss the long-term data of recently FDA-approved PPAR-δ agonist seladelpar?
Related Videos
Related Content
